Special Issue "Nanocarriers in Vaccine Applications"

Dear Colleagues,

The discovery of vaccines is by far the most important medical invention in recent centuries and has contributed to the eradication of many diseases. The essential elements to be considered when designing a vaccination include the antigen, adjuvant, and/or delivery method. To fully harness the promise of vaccine research for managing or eradicating illnesses, new technologies are needed against rising disease threats. Nanotechnology has been highlighted as an important contributor in vaccine development for adjuvants and delivery systems. The combination of emerging nanotechnologies and subunit vaccines has led to the foundation of effective and safe vaccine development. In recent years, the effective use of lipid nanoparticle-based mRNA COVID-19 vaccines in clinical settings has underlined the potential of nanotechnology in vaccine development. Nanovaccines are thought to have advantages over traditional vaccines in terms of lymph node accumulation, antigen assembly, and antigen presentation. Nanocarriers enhance the bioavailability of the vaccine and act as adjuvants to stimulate a higher immune response (humoral and cell-mediated immune responses), increasing the vaccination's efficacy. The four major categories of nanovaccines include those based on lipids, polymers, inorganic vectors, and biologically derived materials. It is also necessary to consider the potential benefits and drawbacks of different approaches for developing nanotechnology-based vaccines to induce desired immune systems.

The Special Issue's aim is to highlight the development of new vaccines and vaccines that have been improved using novel nanocarrier formulations, with a focus on preclinical and clinical evaluation. This issue will also include articles that provide critical reviews of current advancements and updates on nanocarrier-based vaccines from experts in relevant fields.

We look forward to receiving your contributions.

Dr. Robin Kumar
Dr. Jairam Meena
Dr. Ruchika Dehinwal
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• vaccine
• nanocarrier
• nanovaccine strategies
• antigen
• adjuvant
• immune response
• antibody
• active immunity
• protective efficacy
• disease prevention